In total parenteral nutrition (TPN), which is also known as parenteral hyperalimentation, all of the patient's daily nutritional requirements are supplied by infusing nutrients directly into the systemic circulation. TPN is widely employed in a variety of pathophysiological settings for the nutritional support of patients with conditions requiring complete bowel rest (e.g., some stages of Crohn's disease, ulcerative colitis, and severe pancreatitis) or pediatric patients with gastrointestinal disorders (e.g., congenital anomalies and protracted nonspecific diarrhea). In particular, TPN therapy is essential for low-birth-weight neonates and infants with inflammatory bowel disease or Crohn's disease. However, it has been recognized that the excessive administration of fat-free TPN is associated with the development of cholestasis 1) and hepatic steatosis, 2) which can be fatal in neonates or infants who do not receive oral feeding for a prolonged period. In addition to such pathophysiological abnormalities, hepatic drug metabolizing activity is markedly affected by fat-free TPN in humans 3) and rats. 4) Knodell et al. reported that 7-d parenteral infusion of a hyperalimentation solution containing glucose, amino acids, and electrolytes via the jugular vein led to a decrease in cytochrome P450-mediated oxidative metabolism in rats.
In total parenteral nutrition (TPN), which is also known as parenteral hyperalimentation, all of the patient's daily nutritional requirements are supplied by infusing nutrients directly into the systemic circulation. TPN is widely employed in a variety of pathophysiological settings for the nutritional support of patients with conditions requiring complete bowel rest (e.g., some stages of Crohn's disease, ulcerative colitis, and severe pancreatitis) or pediatric patients with gastrointestinal disorders (e.g., congenital anomalies and protracted nonspecific diarrhea). In particular, TPN therapy is essential for low-birth-weight neonates and infants with inflammatory bowel disease or Crohn's disease. However, it has been recognized that the excessive administration of fat-free TPN is associated with the development of cholestasis 1) and hepatic steatosis, 2) which can be fatal in neonates or infants who do not receive oral feeding for a prolonged period. In addition to such pathophysiological abnormalities, hepatic drug metabolizing activity is markedly affected by fat-free TPN in humans 3) and rats. 4) Knodell et al. reported that 7-d parenteral infusion of a hyperalimentation solution containing glucose, amino acids, and electrolytes via the jugular vein led to a decrease in cytochrome P450-mediated oxidative metabolism in rats. 4) Thus, TPN therapy without fat may affect the pharmacokinetics of therapeutic drugs and eventually induce adverse events in patients.
The hepatic cytochrome P450 (CYP) isoenzymes are involved in the detoxification of endogenous and exogenous compounds for further metabolism or elimination. Therapeutic drugs are mainly metabolized by the CYP1, CYP2, and CYP3 isoenzymes in the CYP families.
5) The CYP4 family has been shown to be related to the metabolism of fatty acids. 6) Since the capacity of CYP-mediated drug metabolism in the neonate or infant is lower than that in the adult, 7, 8) severe adverse reactions may occur in pediatric patients if additional pharmacotherapy is required during fat-free TPN therapy. It is therefore important to elucidate the specific changes in the hepatic CYP isoenzymes during fat-free TPN in the neonate or infant and to clarify the effects of including fat in the TPN regimen. However, to the best of our knowledge, there have been no reports in the literature focusing on the changes in hepatic CYP isoenzymes during TPN therapy.
Intravenous fat emulsions, especially soybean oil, are now available as a source of essential fatty acids in patients receiving TPN, and "three-in-one" solutions containing a mixture of amino acids, glucose, and lipid have been found to be clinically safe, stable, and economical. However, there has been some controversy regarding the possible advantages of including fat in the TPN regimen. Some studies have found that intravenous fat infusion can improve hepatic dysfunction, 9) but others have reported that it may induce hepatic steatosis and progressive cholestasis in humans 10) and rats.
11)
We have recently developed an infant rat model of hepatic dysfunction and steatosis induced by overdose of fat-free TPN.
12) Using this animal model, we have demonstrated that metabolic complications such as those related to fat in the liver can be significantly improved by including fat in the TPN regimen. 12, 13) In the present study, we therefore focused on investigating the changes in the mRNA expression of hepatic CYP isoenzymes in this infant rat model following the administration of TPN with or without soybean oil emulsion. The high-sensitivity real-time reverse transcription-polymerase chain reaction (RT-PCR) method with newly designed probes was employed. In this paper, we present the first report that the administration TPN without fat induced marked and selective down-regulation of hepatic CYP mRNAs in the infant rat and that the addition of soybean oil emulsion to the TPN regimen dramatically reduced the down-regulation of CYP mRNAs and prevented the development of hepatic dysfunction. Surgery, Infusion of Parenteral Nutrition, and Sample Collection Infant (3-week-old) male Sprague-Dawley rats (Charles River Japan) weighing 60-70 g were randomly allocated to three groups (nϭ4 or 5 in each group): group 1 received an oral diet, group 2 received TPN without fat, and group 3 received TPN with 20% of calories from fat emulsion. Group 1 is referred to as the oral diet group, and groups 2 and 3 are collectively referred to as the TPN groups. In the TPN groups, after the rats were fasted overnight, a catheter for the infusion of parenteral nutrition was placed in the jugular vein under general anesthesia with diethyl ether. All TPN regimens were isocaloric (1000 kcal/l) and isonitrogenic. The compositions of the TPN solutions with and without fat are shown in Table 1 . Otsuka MV injection (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) was used to supply vitamins. Infusion was started immediately after cannulation at 3 ml/kg body weight/h for the first 12 h and then increased in a stepwise manner to 10, 20, and then 30 ml/kg/h every 12 h. On the third day, the infusion rate was increased to 40 ml/kg/h (i.e., full-dose TPN) and maintained at that level thereafter. The total experimental period was 4 d, and continuous infusion was maintained with a Terufusion pump (Terumo Co., Tokyo, Japan). An administration rate of 40 ml/kg/h, which was found to induce abnormal changes in blood chemistry values suggestive of cholestasis and hepatic dysfunction in the dose selection study, was used in the present study. The animals were then anesthetized with diethyl ether and the abdominal cavity was opened. Blood samples were drawn from the vena cava and the animals were killed by exsanguination, after which the entire liver was rapidly excised. The blood samples were placed in tubes with or without EDTA-Na 2 and were immediately centrifuged. Total RNA was extracted from the liver using the Rneasy ® Mini kit and QIAshredder TM . Biochemical Examination Serum samples were analyzed for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) using an autoanalyzer (Model 7170, Hitachi Co., Tokyo, Japan). AST and ALT activities were measured by the JSCC transferable method.
Soybean Oil Fat Emulsion Prevents
Oligonucleotides The forward and reverse primers and the TaqMan probes were designed using Primer Express software (Applied Biosystems) from the rat mRNA sequence ( Table 2) . Each primer and/or probe was homology searched by an NCBI BLAST search to ensure that it was specific for the target mRNA transcript. The primers and TaqMan probes were synthesized by QIAGEN (Tokyo, Japan). The TaqMan probes contained 6-carboxyfluorescein (FAM) at the 5Ј end and 6-carboxytetramethylrhodamine (TAMRA) at the 3Ј end and were designed to hybridize to a sequence located between the PCR primers.
Experimental Conditions for TaqMan RT-PCR Total RNA was diluted with yeast tRNA at 50 mg/ml. The RT-PCR assay was performed in 50 ml of TaqMan One-Step RT-PCR Master Mix Reagents containing 300 nM forward primer, 900 nM reverse primer, 200 nM TaqMan probe, and 25 ng of total RNA. Amplification and detection were performed using the ABI PRISM 7700 Sequence Detector system (Applied Biosystems) with the following profile: 1 cycle of 48°C for 30 min, 1 cycle of 95°C for 10 min, and 40 cycles each of 95°C for 15 s and 60°C for 1 min.
Statistical Analysis Samples were deemed positive at any given cycle when the value of the emitted fluorescence was greater than the threshold value calculated by the instrument's software (Sequence Detector Ver. 1.9.1). The threshold cycle (Ct), which is defined as the cycle at which PCR amplification reaches a significant value (i.e., usually 15 times the standard deviation of the baseline), was recorded as the mean value. The relative expression of each mRNA was calculated by the DCt method (where DCt is the value obtained by subtracting the Ct value of b-actin mRNA from the Ct value of the target mRNA), as employed in previous studies. 14, 15) Specifically, the amount of target mRNA relative to b-actin mRNA was expressed as 2
. Data for housekeeping genes were expressed as the ratio of the mean value in group 1 and data for CYPs were expressed as the ratio of target mRNA to b-actin mRNA. Studies were conducted in duplicate and data are shown as meanϮS.D. for 4 or 5 rats. The statistical significance of differences between mean values was analyzed by the Tukey's test.
RESULTS

Biochemical Findings
In group 2 (fat-free TPN), the serum AST level was 1256Ϯ364 U/l, which was significantly higher (pϽ0.001) than the value of 89Ϯ3 U/l in group 1 144 Vol. 28, No. 1 (oral diet), and the serum ALT level was 249Ϯ100 U/l, which was significantly higher (pϽ0.01) than the value of 38Ϯ2 U/l in group 1. However, in group 3 (fat-containing TPN), the serum AST level was 112Ϯ39 U/l and the serum ALT level was 33Ϯ12 U/l, which were not significantly different from those in group 1. Housekeeping Gene mRNA Expression Table 3 shows the changes in the mRNA expression of the liver housekeeping genes b-actin, b-2 microglobulin (B2M), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), b-glucuronidase (Gusb), hypoxanthine phosphoribosyltransferase (Hprt), peptidylprolylisomerase A (Ppia), and transferrin receptor (Tfrc) in infant rats that received TPN for 4 d. The mRNA expression of all housekeeping genes did not show down-regulation by the administration of TPN regimens with or without fat. For GAPDH and Tfrc, hepatic mRNA levels were significantly induced ( pϽ0.01, pϽ0.05). On the other hand, no significant differences were observed between the three groups in the mRNA expression of b-actin, B2M, Gusb, or Hprt. Therefore, b-actin was used as the endogenous control in the measurement of target mRNAs in this study.
CYP mRNA Expression Figure 1 shows the changes in the mRNA expression of hepatic CYP1A2, CYP2A1, CYP2A2, CYP2B2, CYP2C11, CYP2D1, CYP2D2, CYP2E1, CYP3A1, CYP3A2, and CYP4A1 in infant rats that were fed an oral diet or received TPN for 4 d. The ratio of CYP1A2 to b-actin in group 2 decreased markedly to 0.76% of that in group 1, whereas the ratio of CYP1A2 to bactin in group 3 was maintained at 40% of that in group 1.
With regard to the members of the CYP2 family, the ratios of CYP2A1 and CYP2A2 to b-actin in group 2 decreased to 1.4% and 2.4%, respectively, of those in group 1, but the ratios in group 3 were maintained at 45% and 53% of those in group 1. The ratios of CYP2B2 and CYP2C11 to b-actin in group 2 decreased to 1.3% and 1.8% of those in group 1, respectively, but the ratios in group 3 were maintained at 84% and 73% of those in group 1. The ratios of CYP2D1, CYP2D2, and CYP2E1 to b-actin in group 2 decreased to 21%, 11%, and 1.8% of those in group 1, respectively, but the ratios in group 3 were maintained at 58%, 53%, and 32% of those in group 1. In the CYP3 family, the ratios of CYP3A1 and CYP3A2 to b-actin in group 2 decreased to 22% and 3.1% of those in group 1, respectively, but the ratios in group 3 were maintained at 37% and 39%. The ratio of CYP4A1 to b-actin in group 2 decreased to 31% of that in group 1, whereas the ratio in group 3 was maintained at 73% of that in group 1.
DISCUSSION
We have recently established an experimental TPN model of pathophysiological liver dysfunction in the infant (3-weekold) male Sprague-Dawley rat following overdose of fat-free TPN. 12, 13) It should be noted that liver dysfunction is the most common complication associated with TPN. In these studies, the animals that received TPN with 0% of calories from fat emulsion were found to have marked increases in the levels of liver enzymes as well as fatty changes in the liver by microscopic examination, while the animals that received TPN with 20% or 40% of calories from fat emulsion, despite the excessive administration of glucose, did not exhibit liver dysfunction or fatty changes. 12, 13) Furthermore, it was clear that the infusion of excessive glucose caused increased hepatic lipogenesis and decreased lipolysis. 13) Generally, a dosage of 12.5 kcal/kg/h is required to maintain body weight in normal adult rats. In infant rats, the optimum dosage of such a TPN solution should be 25-28 ml/kg/h because the basal metabolic rate of infants is higher than that of adults, and infant animals must gain weight. 16) In the present study, an excessive dosage of 40 ml/kg/h was employed to intentionally induce liver dysfunction in infant rats. 12) Based on the findings of biochemical examinations (serum AST and ALT), an overdose of fat-free TPN induced hepatic dysfunction, as we reported previously. 12, 13) It is notable that the addition of fat to the TPN regimen completely prevented the development of liver dysfunction in the infant rats. In this infant rat TPN model with liver dysfunction, changes in the mRNA expression of various hepatic cytochrome P450 isoenzymes were investigated using the high-sensitivity real-time RT-PCR method. Furthermore, the effects of the inclusion of fat emulsion in the TPN regimen on CYP mRNA expression were evaluated. The TaqMan method is exquisitely specific and permits the quantitative evaluation of rat hepatic CYP mRNA expression, as reported previously. 14, 15) The mRNA of each hepatic CYP isoenzyme was expressed heterogeneously in infant rats fed a normal diet: CYP2E1Ͼ ϾCYP3A2ϾCYP2D1ϭCYP2D2ϾCYP3A1Ͼ CYP2B2ϾCYP1A2ϭCYP2C11ϾCYP2A1ϭCYP4A1Ͼ CYP2A2 (Fig. 1) . When infant rats received an overdose of fat-free TPN for 4 d, all of these mRNA levels were markedly decreased. In particular, the mRNA levels of CYP1A2, 2A1, 2A2, 2B2, 2C11, 2E1, and 3A2 were decreased to 0.76 to 3.1% of those in the oral diet group. On the other hand, the 7 housekeeping genes were not down-regulated by the fat-free TPN regimen compared with the oral diet group, even though hepatic dysfunction developed in the infant rats. These findings indicate that the down-regulation of mRNA expression by the administration of fat-free TPN selectively affected CYP mRNAs in the infant rat liver.
However, such down-regulation of CYP gene expression was prevented, with levels maintained at 32 to 84% of those in the oral diet group, by the addition of a fat emulsion to the TPN regimen (Fig. 1) . In particular, the mRNA expression of CYP2B2 and CYP2C11 in group 3 was dramatically increased from 1.3 to 84% and from 1.8 to 73% of that in the oral diet group, respectively. It has been reported that induction of hepatic CYP2B1 and 2B2 occurred in rats fed a 20% corn oil diet compared with rats fed a fat-free diet, whereas no induction of CYP2E1 was observed. 17, 18) Among the members of the CYP2 family, CYP2B is likely to be more sensitive to fat ingestion. With regard to the CYP2C isoforms, the ethylmorphine demethylase activity (CYP2C11 and CYP2C12) and the benzphetamine dealkylase activity (CYP2C11) in rats that received TPN without fat were found to be decreased by 41% and 73%, respectively, compared with rats that received the same hyperalimentation solution enterally. 4) These findings indicate the great importance of including fat in the hyperalimentation regimen in order to maintain the hepatic drug oxidation capability in animals.
It is known that, in adult rats, CYP2A1 is female-specific and CYP2A2 is male-specific. 19) The results of the present study in the male infant rat showed that the mRNA expression of CYP2A1 (0.595Ϯ0.174) was the same as that of CYP2A2 (0.395Ϯ0.147), suggesting immature gender development in 3-week-old male rats. In fact, Imaoka et al. have reported that the level of P4502A1 reaches a maximum at 3 weeks of age in rats of both sexes. 19) The results of the present study support the previous observation that the erythromycin demethylase activity (CYP3A2) in rat liver was markedly decreased by the admin- istration of TPN in the absence of fat. 4) Drugs such as prednisolone and cyclosporin A, which are metabolized by CYP3A4 in the human, 20, 21) are commonly prescribed to pediatric patients with inflammatory bowel disease or Crohn's disease. If such patients require parenteral hyperalimentation, the results of the present study indicate that the use of fatfree TPN may induce a lethal adverse drug reaction due to impaired drug metabolism resulting from the decreased expression of CYP3A4. The human CYP3A isoform, which is a major isoform in the perinatal period and infancy, 8) appears to play critical roles in drug metabolism and/or drug interaction in pharmacotherapy in pediatric patients. Including fat in the TPN regimen is essential to prevent adverse drug reactions.
The human CYP4 isoforms are known to be responsible for the metabolism of fatty acids such as arachidonic acid and for the w,w-1-hydroxylation of prostaglandins.
6) Therefore, the down-regulation of CYP4A1 mRNA, which inhibits further lipid metabolism, may be responsible for the hepatic steatosis induced by overdose of fat-free TPN. On the other hand, such down-regulation of CYP4A1 mRNA was less pronounced and liver dysfunction was not induced in the group that received TPN with soybean oil emulsion. The significance of lipid-based TPN solutions in terms of drug metabolism has been debated in previous reports. Ross et al. observed that the pharmacokinetics of antipyrine returned to normal levels when lipid-based PN was used in rats. 22) On the other hand, Zaman et al. reported that the incorporation of lipid in PN solutions promoted steatosis and exacerbated the reduction in the rate of lidocaine metabolism in rats. 23) The results of the present study clearly showed that the inclusion of soybean oil in the TPN regimen prevented the downregulation of both the hepatic detoxification system and fatty acid metabolism observed in infant rats that received fat-free TPN.
The mechanism responsible for this phenomenon has yet to be elucidated. In some studies, carbohydrates reduced the metabolism of drug substrates in vivo and in vitro without affecting microsomal protein or total CYP content. 24, 25) A number of findings in the present study suggest that the mechanism of down-regulation of liver CYP mRNA expression by fat-free TPN involves multiple factors related to the metabolism of fatty acids, including nuclear receptors. 26, 27) The findings of the present study clearly demonstrated the usefulness of soybean oil as a lipid source in the hyperalimentation solution for TPN in the infant rat model. The TaqMan RT-PCR method employed in this study showed that overdose of fat-free TPN induced the hepatic mRNA downregulation of the CYP1, 2, and 3 families involved in drug metabolism, as well as the mRNA down-regulation of the CYP4 family involved in fatty acid metabolism, despite the fact that the expression of housekeeping genes was unaffected. Therefore, infant rats that received an overdose of fatfree TPN readily developed hepatic dysfunction with steatosis, with a marked decrease in drug metabolizing capability. When patients receiving long-term TPN require certain types of pharmacotherapy, the changes in hepatic CYP expression may cause severe adverse drug reactions. However, such adverse reactions are dramatically reduced by the addition of a fat emulsion to the TPN regimen, indicating the importance of including fat in TPN for infants.
